MedTrace Logo

Respiratory Microbiota and Immune Response in CVID

NCT06173128 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2026-03-06

No results posted yet for this study

Summary

Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency. Respiratory ailments are the most frequent complications of CVID, with chronic pulmonary disease developing in 30-60% and even more experiencing frequent acute respiratory infections. This project aims to establish cutting-edge approaches to study pulmonary biology in CVID and apply novel bioinformatics strategies to study complex interactions among microbes and host cells by direct sampling of the respiratory tract. The central hypothesis for this research is that antibody (Ab) deficiency in CVID alters respiratory microbiota and host interactions to drive pulmonary disease.

Conditions

  • CVID

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Boston University

    lead OTHER

Principal Investigators

  • Paul J Maglione, MD PhD · Boston University Chobanian & Avedisian School of Medicine, Pulmonary Center

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2026-02-15
Completion
2026-02-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06173128 on ClinicalTrials.gov